FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease – Biogen

Written by

admin

in

  1. FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease  Biogen
  2. Eisai and Biogen Self-Injected Alzheimer Drug Wins US Approval  Bloomberg.com
  3. FDA approves Eisai and Biogen’s subcutaneous Leqembi, gaining new ground in competition against Lilly  Endpoints News
  4. US FDA approves injectable version of Eisai-Biogen’s Alzheimer’s drug  MarketScreener
  5. Biogen, Eisai Snatch A Highly Anticipated Alzheimer’s Win  Investor’s Business Daily

Continue Reading

More posts